Shares of Vor Biopharma Inc. (NYSE:VOR – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.92.
Several equities analysts have recently weighed in on VOR shares. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Friday, September 6th. Barclays decreased their price target on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Friday, September 6th.
Institutional Trading of Vor Biopharma
Vor Biopharma Stock Performance
Shares of Vor Biopharma stock opened at $0.69 on Thursday. The stock has a market capitalization of $47.11 million, a P/E ratio of -0.39 and a beta of -0.35. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $3.14. The stock’s 50-day simple moving average is $0.88 and its 200 day simple moving average is $1.28.
Vor Biopharma (NYSE:VOR – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). Equities research analysts forecast that Vor Biopharma will post -1.51 EPS for the current fiscal year.
About Vor Biopharma
Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Read More
- Five stocks we like better than Vor Biopharma
- The How and Why of Investing in Gold Stocks
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- What is a Secondary Public Offering? What Investors Need to Know
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- What Are Dividend Achievers? An Introduction
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.